DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Inhibition assay are 15

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_4088	Bafilomycin A1	Antibiotics	NA	Ebola virus	Mayinga	NA	Inhibition assay	Decrease (50 %)	Experimental	26069727
DrugRepV_4089	Bafilomycin A1	Antibiotics	NA	Ebola virus	Bundibugyo	NA	Inhibition assay	Decrease (50 %)	Experimental	26069727
DrugRepV_4090	Bafilomycin A1	Antibiotics	NA	Marburg virus	Lake Victoria isolate	NA	Inhibition assay	Decrease (50 %)	Experimental	26069727
DrugRepV_4091	Bafilomycin A1	Antibiotics	NA	Influenza virus	A/turkey/ England/50-92/91		Inhibition assay	Decrease (50 %)	Experimental	26069727
DrugRepV_4092	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Mayinga	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4093	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Ebola virus	Bundibugyo	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4094	Chloroquine	Malaria	Malaria	Marburg virus	Lake Victoria isolate	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4095	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Influenza virus	A/turkey/ England/50-92/91		Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4096	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Ebola virus	Bundibugyo	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4097	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Marburg virus	Lake Victoria isolate	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4098	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Influenza virus	A/turkey/ England/50-92/91		Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4099	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Ebola virus	Mayinga	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4100	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Ebola virus	Bundibugyo	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4101	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Marburg virus	Lake Victoria isolate	NA	Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4102	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Influenza virus	A/turkey/ England/50-92/91		Inhibition assay	Decrease (50 %)	Approved	26069727